Search results
Results from the WOW.Com Content Network
Cost: $7 | Active ingredients: Lidocaine | Type: Cream | Amount: 4.3 ounces. Lidocaine is another popular ingredient found in pain relief creams. It's a topical anesthetic that's often used to ...
Bengay and similar products, such as Flexall, Mentholatum, Capzasin and Icy Hot, variously contain menthol, methyl salicylate (oil of wintergreen), and capsaicin as active ingredients and have a potential to cause first-to-third-degree chemical burns. [4] [5] Some people have been hospitalized after receiving such burns. [4]
While there are over 100 types of arthritis and related conditions, Dr. Gendai Echezona, a fellowship-trained, triple board-certified anesthesiologist specializing in interventional pain ...
Leflunomide, sold under the brand name Arava among others, is an immunosuppressive disease-modifying antirheumatic drug , [8] used in active moderate-to-severe rheumatoid arthritis and psoriatic arthritis. It is a pyrimidine synthesis inhibitor that works by inhibiting dihydroorotate dehydrogenase. [9] Bottle of Leflunomide (Arava) and tablet
Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polyarticular course juvenile idiopathic arthritis, and ulcerative colitis. [8] [9] [10] It is a janus kinase (JAK) inhibitor, [8] [9] discovered and developed by the National Institutes of ...
Take the strain out of your hands and wrists.
RUB A535 (also known as Antiphlogistine) is a rubefacient introduced in 1919 and manufactured by Church & Dwight in Montreal, Quebec, Canada. [1]A 1914 advertisement. While little known outside of Canada, it is used there for the treatment of tough muscle pain, arthritic pains, rheumatic pains, bursitis, lumbago, etc. [2] [3] Church and Dwight say on their website that nearly all the research ...
Arthritis Australia is a charitable not-for-profit organisation advocating for people with arthritis and musculoskeletal conditions. Arthritis Australia awards nearly $1 million in annual funding to researchers engaged in basic and clinical research that aims to further knowledge of arthritis and develop treatments and cures.